INTRODUCTION
============

Partition-deficient (PAR) mutant genes encoding PAR proteins and PCK-3 (the orthologue atypical PKC \[aPKC\]) were identified in *Caenorhabditis elegans* as essential components of cell polarity mechanisms ([@B24]). These proteins are highly conserved in metazoan evolution and participate in polarization of various cell types, including epithelial apicobasal polarity ([@B65]; [@B58]; [@B13]). Typically, the aPKC-Par6-Par3 polarity complex is highly polarized itself ([@B13]). However, most of the evidence supporting a role of aPKC in epithelial apicobasal polarity in vertebrates was obtained in polarized tissue culture epithelial cell lines, such as Madin--Darby canine kidney (MDCK) and Caco-2 (intestine) cells ([@B64]; [@B43]; [@B76]). Global mouse knockout models for both aPKC isoforms (PKCι and ζ) were not informative regarding the role of aPKC in polarity in vivo. The PKCι knockout is embryonic lethal ([@B5]), whereas the PKCζ knockout model displays a mild phenotype with defective immune response and compromised NF-κB activation in B-lymphocytes ([@B46])

Two other groups independently reported the use of conditional PKCι-deficient mice for studies of epithelia ([@B31]; [@B11]). In one case, defects of adherens junctions in neuroepithelial cells were found ([@B31]), whereas in the other, the status of apicobasal polarity was not reported. [@B11], however, reported an intriguing hypersensitivity of PKCι-knockout mice to chemical colitis, compatible with an anti-inflammatory role of this kinase, but evidence for a specific role in modulating the NF-κB pathway was lacking. In contrast, the role of aPKC in other cell types has been extensively studied, especially in relationship to its role in glucose metabolism ([@B20]; [@B19]) and *activation* of NF-κB ([@B16]). In those functions, aPKC typically partners with p62 via the N-terminal PB1 domain ([@B50]) rather than Par6 in the PAR polarity complex ([@B13]).

Our interest in the possible role of aPKC in inflammatory pathways was sparked when we observed that aPKC is deeply down-regulated in intestinal epithelia under proinflammatory stimuli in Caco-2 cells, a mouse model of colitis ([@B48]), and samples from human inflammatory bowel disease (IBD) patients ([@B71]). We demonstrated that aPKC down-regulation is posttranslational, due to destabilization, and under the control of NF-κB activation ([@B48]). It was natural to ask what consequences, if any, result from loss of aPKC in inflammation. Overexpressing wild-type and constitutively active PKCι in Caco-2 cells, we found *inhibition* of basal NF-κB activity. Furthermore, there was no detectable effect on apicobasal polarity by a constitutively active mutant defective in the PB1 domain and, thus, depolarized. These results were intriguing because they are not consistent with prevalent views of aPKC activating NF-κB. We hypothesized that different effects of aPKC on NF-κB might be tissue specific or perhaps due to the transformed status of Caco-2 cells.

This work was undertaken to test the hypothesis that PKCι down-regulation affects both apical polarity and inflammation in vivo. To that end, we used a PKCι^flox/flox^ mouse developed in our facility to achieve a conditional knockout in intestinal epithelia. The results showed a modest role of aPKC in the maintenance of apical polarity and a critical control of NF-κB activation.

RESULTS
=======

Effects of the conditional PKCι knockout
----------------------------------------

Exon 4 of the gene encoding PKCι (*Prkci*) ([Figure 1A](#F1){ref-type="fig"}) was floxed by breeding *Prkci*^flox/flox^ animals with transgenic mice expressing CRE under a 12.4-kb villin promoter. In these animals, CRE is expressed in the intestinal epithelium ([@B45]), active in all lineages, and possibly expressed in stem cells ([@B39]). To analyze the phenotype, we performed studies with an antibody that recognizes the phosphorylated turn domain in both aPKC isoforms, ι and ζ (T555 and T560, respectively). Because the turn domain is autophosphorylated, it reports that the kinase is in the active conformation. Therefore this strategy enabled us to identify cells lacking both aPKC isoforms so that the results would not be confused by isoform redundancy. The characteristic signal of aPKC in the tight junction region in villus enterocytes ([Figure 1B](#F1){ref-type="fig"}, arrows) and colonocytes ([Figure 1E](#F1){ref-type="fig"}, arrows) was missing in the *Prkci*^flox/flox^ Vil-CRE+ (hereafter referred to as KO). However, we found aPKC signal in the intestinal glands ("crypts"; [Figure 1, C](#F1){ref-type="fig"}, arrow in [E](#F1){ref-type="fig"}). Using an isoform-specific PKCζ antibody, we found that this isoform was up-regulated in the KO crypts ([Figure 1D](#F1){ref-type="fig"}) but not in the surface epithelium (colon) or in the villus (small intestine), except for isolated patches of cells at the tip of villi (unpublished data). The subcellular apical localization of PKCζ in KO crypts was identical to that of total aPKC in control animals ([Figure 1, C and D](#F1){ref-type="fig"}). This is important because the predicted protein encoded by *Prkci* exons 1--3, if stable, would comprise the PB1 domain, which is responsible for binding to Par6 and, consequently, aPKC apical localization and activation ([@B23]). Competition for PB1 domain partners by the possible product of the floxed *Prkci* gene is therefore unlikely. For the interpretation of the results in the following sections, it is necessary to bear in mind that the intestinal epithelial cells display a very fast turnover. The stem cells are located at or near the bottom of the crypts, and proliferating cells move along the crypt. Therefore up-regulation of PKCζ must follow loss of PKCι, acting as a redundant aPKC only in the crypts.

![Effect of conditional *Prkci*^flox/flox^ Vil-CRE± (KO) on aPKC protein expression. (A) Structure of the targeted flox/flox insertion in the *Prkci* locus after homologous recombination. Numbers in gray represent *Prkci* exons. Boxes represent the selection genes. Triangles represent the targets for Flp (FRP) and CRE (loxP) recombinases. Arrows represent orientation of genotyping primers. (B) Villus enterocytes or (C) crypts in small intestine frozen sections were stained with anti--phosphorylated aPKC turn domain antibody, which recognizes the active conformation of PKCι/λ and ζ. (D) Crypts in the small intestine mucosa stained with an isoform-specific antibody against PKCζ that does not recognize the ι isoform. (E) Large intestine mucosa sections were processed with anti--p-PKCι/λ antibody as in B and C. Arrows point at aPKC signal in the apical domain. Bars, 10 μm (B), 25 μm (C, E), 20 μm (D).](2186fig1){#F1}

Villus enterocytes are differentiated and postmitotic ([@B68]). The lifespan of these cells as they move from the base of the villus to desquamation at the tip is ∼2 d ([@B17]). This is the maximum time villus enterocytes lack aPKC activity after spontaneous down-regulation of PKCζ in the KO villus. In summary, these conditional PKCι-deficient mice lack all aPKC activity (PKCι + ζ) in the villus (small intestine) or surface epithelia (colon) but retain aPKC activity in the crypts because of compensatory expression of redundant PKCζ.

The KO animals developed normally, the proportion of KO pups born alive was Mendelian, and weight gain was indistinguishable from that of the controls ([Figure 2A](#F2){ref-type="fig"}). Previous studies showed that the conditional PKCι defect in enterocytes does not result in changes in proliferation or apoptosis in the absence of chemical injury ([@B11]). The proportion of goblet cells was found to be normal as well ([@B11]). Here we found no changes in the number or localization of Paneth cells ([Figure 2B](#F2){ref-type="fig"}, arrows), suggesting that the loss of PKCι does not affect lineage determination, at least in the presence of compensatory PKCζ. The intestinal barrier permeability, measured by diffusion of 3-kDa fluorescent dextran into the blood, showed a significant threefold increase in the KO animals ([Figure 2C](#F2){ref-type="fig"}). Such an increase was abolished by prior treatment with oral sulfasalazine (SS), an inhibitor of NF-κB, which interferes with IKKα and β ([@B70]; [@B73]). Sulfasalazine is approved by the U.S. Food and Drug Administration for use in IBD patients ([@B52]) and is also safe for use in rodents. These results led us to ask about the extent to which, if any, the total loss of aPKC in villus enterocytes would affect apicobasal polarity or junction structure.

![Functional phenotype of *Prkci*^flox/flox^ Vil-CRE± (KO) mice. (A) Weight gain after birth for male and female KO (blue diamond) or control littermates (red squares, *Prkci*^flox/flox^ Vil-CRE- or *Prkci*^flox*/*−^ Vil-CRE+; lm). (B) Hematoxylin and eosin images showing the bottom of the crypts displaying Paneth cells (arrow) in control littermates and KO mice. Bar, 20 μm. (C) Female and male control lm and KO mice from 3 to 5 mo old were stomach gavaged with 3-kDa fluorescent dextran and killed 3 h later; fluorescence in plasma was measured. Some animals received NF-κB inhibitor SS in the water before gavage. Values are relative to one control animal in each group. Horizontal lines represent average values. \*Kruskal--Wallis test, *p* \< 0.05.](2186fig2){#F2}

aPKC is dispensable for maintenance of epithelial polarity in differentiated enterocytes but necessary for correct localization of direct targets
-------------------------------------------------------------------------------------------------------------------------------------------------

The question of how loss of aPKC affects apicobasal polarity is relevant because these kinases are deeply down-regulated in intestinal inflammation ([@B71]). We tested polarized proteins and tight junction (TJ) markers. Several markers remained well polarized in the villus enterocytes despite the lack of aPKC. Brush border actin, NHE3, and occludin ([Figure 3](#F3){ref-type="fig"}), as well as alkaline phosphatase, Par3, and ZO-1 ([Figure 4A](#F4){ref-type="fig"}), were normally localized in the KO. An increase in the basolateral F-actin signal was noted in the KO villus enterocytes ([Figure 3](#F3){ref-type="fig"}, arrow). The ultrastructure of brush borders ([Figure 4, B and C](#F4){ref-type="fig"}) and apical junctional complexes ([Figure 4, D and E](#F4){ref-type="fig"}) was also indistinguishable ([Figure 4, D and E](#F4){ref-type="fig"}). Claudin-4, which is not confined to TJs in intestinal epithelia and is expressed almost exclusively in villi ([@B59]), was deeply down-regulated in the KO ([Figure 3](#F3){ref-type="fig"}). Finally, as expected, the homologue of *Drosophila* lethal giant larvae, LLGL2, a known aPKC target ([@B37]), changed its distribution from diffuse cytoplasmic signal in control enterocytes to cortical, including the apical pole in KO ([Figure 3](#F3){ref-type="fig"}).

![Apicobasal polarity and junction markers in *Prkci*^flox/flox^ Vil-CRE± (KO) mice. Frozen sections of villus enterocytes from KO and control littermates (lm) were processed with fluorescent phalloidin or the following antibodies: Na^+^/H^+^-exchanger 3 (NHE3), claudin-4, occludin, and the human homologue of *Drosophila* lethal giant larvae protein 2 (LLGL2). Arrow points at increased lateral F-actin signal. Bars, 10 μm, except claudin-4, 25 μm.](2186fig3){#F3}

![Apical and junction markers and intestinal epithelium ultrastructure in *Prkci*^flox/flox^ Vil-CRE± (KO) mice. (A) Frozen sections of villus enterocytes from KO and control littermates (lm) were processed with the following antibodies: alkaline phosphatase (iAP), active (pT567) ezrin, ezrin, ZO-1, and human homologue of Par3. Ezrin inset, cross sections of the crypts displaying normal apical ezrin levels. Bars, 10 μm (iAP, pT567ezrin), 45 μm (ezrin), 25 μm (ZO-1, Par3). (B--E) Electron microscopy images of villus enterocytes from control (B, D) or KO (C, E) animals. Bars, 10 μm (B, C), 0.5 μm (D, E).](2186fig4){#F4}

Both total ezrin and p-T567 ezrin signals were significantly decreased in the KO villus enterocytes, with the exception of positive patches ([Figure 4A](#F4){ref-type="fig"}). However, ezrin was normally localized to the apical domain in the crypts ([Figure 4A](#F4){ref-type="fig"}, inset). This is consistent with our finding that PKCι phosphorylates ezrin in cultured intestinal Caco-2 cells ([@B72]). Because this result seems to contradict the normal ultrastructure of brush borders in KO enterocytes ([Figure 4C](#F4){ref-type="fig"}), we further quantified apical and cytoplasmic ezrin signals in confocal images. There was a 15-fold decrease in average pixel intensity for the brush border ([Figure 5, A and B](#F5){ref-type="fig"}, black bars; note the difference in the pixel-value scales) in the KO enterocytes. However, despite the fact that it is difficult to see when the images are acquired at the same gain, there was a significant remnant of apical ezrin, well above the background level in the KO ([Figure 5B](#F5){ref-type="fig"}). We conclude that a substantial fraction of T567 ezrin phosphorylation depends on aPKC activity.

![Quantification of ezrin distribution in control littermates (lm) or *Prkci*^flox/flox^ Vil-CRE + (KO) villus enterocytes. (A) Pixels in the red channel of images of frozen sections of villus enterocytes showing ezrin distribution as in [Figure 4](#F4){ref-type="fig"} were quantified in ROIs randomly located at the apical edge of cells (a) or in the supranuclear cytoplasm (c). Enterocytes were randomly selected in the blue channel at the distal half of the villus but not at the tip. Bar, 10 μm. (B) Quantification of pixel intensities for pT567 ezrin signal in the apical pole (a; black bars) or supranuclear cytoplasm (c; gray bars) ROIs in enterocytes at the distal half of villi. Control, *n* = 20; KO, *n* = 56; *t* test, \**p* \< 0.0001, \*\**p* \< 0.05.](2186fig5){#F5}

With regard to basolateral markers, except for LLGL2 ([Figure 3](#F3){ref-type="fig"}), we did not find any mistargeting to the apical domain. Na^+^-K^+^ATPase images showed variability ([Figure 6A](#F6){ref-type="fig"}) but no apical localization. We also analyzed another basolateral marker, E-cadherin ([Figure 6B](#F6){ref-type="fig"}), and reached a similar conclusion. Finally, we determined pixel values in the basolateral domain for both markers (after background subtraction; [Figure 6C](#F6){ref-type="fig"}). The results indicate that there were no significant differences in the E-cadherin signal and a small but significant increase in Na^+^-K^+^ATPase signal in the KO mice. In summary, the phenotype of basolateral markers in *Prkci*^flox/flox^ Vil-CRE+ villus enterocytes is complex. There are differences in the steady-state levels of expression of different markers: claudin-4 decreases considerably, E-cadherin does not change, and Na^+^-K^+^ATPase slightly increases in the KO. Therefore it is difficult to conceive that a single mechanism can account for all these observations. In addition, considering the normal images of the junctions ([Figure 4, B--E](#F4){ref-type="fig"}), we conclude that there was no global disruption of the lateral domain in the KO enterocytes, although there were changes in the expression of some specific basolateral proteins.

![Expression of basolateral markers in control littermates (lm) or *Prkci*^flox/flox^ Vil-CRE± (KO) villus enterocytes. Frozen sections of villus enterocytes were processed with (A) anti--Na^+^-K^+^ATPase antibody or (B) anti--E-cadherin antibodies. Examples of typical ROIs used for quantification of pixel values for basolateral signal (b) or cytoplasmic background (c) are shown. Bars, 20 μm. (C) Pixel values per cell (ROIs b and c) in littermates (black bars) or KO (gray bars) for Na^+^-K^+^ATPase or E-cadherin. In each case, the results are from three animals; Na^+^-K^+^ATPase, *n* = 41; E-cadherin, *n* = 30; \* *p* \< 0.05.](2186fig6){#F6}

aPKC is an inhibitor of NF-κB activity in vivo
----------------------------------------------

Because PKCι overexpression inhibits NF-κB activity in the Caco-2 (intestinal epithelia) cell line ([@B21]), we hypothesized that the conditional PKCι KO would display intestinal NF-κB activation and, possibly, inflammation. Up to ∼30% of the animals developed anal prolapse after 5 mo of age, which suggested the existence of a mild colitis. A role of PKCι in colitis has been shown ([@B11]). Therefore we wanted to determine whether PKCι-dependent pathways inhibit NF-κB in the absence of or with minimal external proinflammatory stimuli. Accordingly, we focused our attention on the small intestine, where there are small microbial loads and fewer infiltrating myeloid cells than in the colon and local inflammation levels are generally low. Studies in the large intestine and ileum are more common and clinically relevant due to the localization of lesions in IBD. However, the complexity of the interactions among microbiota, epithelia, and immune cells in the colon obscures mechanistic conclusions. Specifically, we analyzed villus enterocytes in which the aPKC defect was complete ([Figure 1](#F1){ref-type="fig"}).

To test the hypothesis, we used various independent criteria of NF-κB activation in conditional PKCι-knockout mouse enterocytes. First, we examined NF-κB nuclear translocation. In control (lm) duodenum villus enterocytes, relA(p65) signal was found excluded from the nuclei. Conversely, *Prkci*^flox/flox^ Vil-CRE+ (KO) enterocytes showed nuclear relA ([Figure 7A](#F7){ref-type="fig"}). The average ratio of nuclear/cytoplasmic relA signal doubled in KO enterocytes, and the difference was significant ([Figure 7B](#F7){ref-type="fig"}). Second, we semiquantitatively measured pSer536 relA signal in epithelial and lamina propria connective tissue (examples of regions of interest \[ROIs\] in [Figure 7C](#F7){ref-type="fig"}, yellow squares). The overall epithelial signal was lower than the lamina propria signal in control cells (lm) but showed similar intensities in KO ([Figure 7, C and D](#F7){ref-type="fig"}). In other words, the levels of phospho-relA signal in the lamina propria were indistinguishable between control and KO, but the levels in epithelial cells significantly increased threefold in the KO enterocytes. As a negative control, we treated the animals with SS and observed minimal levels of phospho-relA signal ([Figure 7, C and D](#F7){ref-type="fig"}).

![Activation of NF-κB in of *Prkci*^flox/flox^ Vil-CRE± (KO) villus enterocytes. (A) Frozen sections of villus enterocytes from untreated KO or littermate control (*Prkci*^flox/flox^ Vil-CRE- or *Prkci*^flox*/*−^ Vil-CRE+; lm) animals processed with anti-relA(p65) (red channel) and DAPI (blue channel). (B) Quantification of the data in A. Average pixel values were measured in ROIs in the cytoplasm or the nucleus. Several cells were measured in four to seven random sections. Each dot represents the average of all of the measured cells from one animal. Horizontal bars show averages of each group. \*Kruskal--Wallis test, H~0~ = control and KO populations are equal, *p* \< 0.003. (C) Frozen sections of intestinal villi were processed with anti-pSer536 relA (red channel) antibody. Animals were untreated controls (lm) or KO, as well as KO mice treated with ROCK inhibitor Y27628 or SS. Yellow squares show examples of randomly located ROIs in epithelia or lamina propria cells used for measurements in D. (D) Quantification of pixel values in images like those in C using ROIs in epithelial cells (black bars) or in lamina propria cells (gray bars) for control littermate (lm) or KO animals or KO animals treated with Y27628 or SS. Data shown as average and SD. \**t* test for difference between average in untreated KO epithelial cells (*n* = 22) and corresponding controls (*n* = 28) or between untreated KO epithelial cells and KO treated with Y27628 (*n* = 29) or between untreated lamina propria cells in KO compared with SS-treated cells, *p* \< 0.001. (E) The sections were processed with anti-ROCK1/2 antibody. Bars, 10 μm.](2186fig7){#F7}

Atypical PKC phosphorylates Rho-associated protein kinase (ROCK) in S1333, T1334, T1337, and S1341. These residues comprise the ROCK Rho-PH binding domain. Phosphorylation renders ROCK inactive and detached from the membrane ([@B32]). In turn, it was shown that ROCK activates IKK ([@B25]; [@B36]). To test the hypothesis that aPKC acts on NF-κB activation pathway through ROCK, we determined the subcellular distribution of ROCK1/2. As expected from evidence in MDCK cells ([@B32]), ROCK cortical and supranuclear distribution increased dramatically in KO enterocytes, but no changes were noted in lamina propria cells ([Figure 7E](#F7){ref-type="fig"}). It is of note that the increase in ROCK cortical localization was more prominent in the apical pole but was also observed in the basolateral domain ([Figure 7E](#F7){ref-type="fig"}). Consistent with this result, the ROCK inhibitor Y27632 significantly rescued \>50% of the increase in phospho-Ser536 relA in the KO enterocytes, with little effect on the same signal in lamina propria cells ([Figure 7, C and D](#F7){ref-type="fig"}). These results suggest that ROCK1/2 may be involved in NF-κB activation in aPKC-deficient enterocytes. We speculate that the widespread subcellular distribution of potentially active ROCK may multiply the effect of highly localized aPKC.

The third criterion to assess NF-κB activity was nonmuscle myosin II light chain phosphorylation (pMLC). NF-κB increases myosin light chain kinase (MLCK) transcription ([@B28]), which phosphorylates myosin II regulatory light chain (MLC), enabling assembly of functional nonmuscle myosin II ([@B22]). Phosphorylation of MLC by MLCK in enterocytes is a hallmark of intestinal inflammation and inflammation-associated carcinogenesis ([@B66]). pMLC signal was consistently higher in all KO animals studied ([Figure 8](#F8){ref-type="fig"}). Treatment of KO animals with SS abrogated pMLC signal increase. These results independently suggest NF-κB activation in *Prkci*^flox/flox^ Vil-CRE+ enterocytes. It is important to note that activation of myosin II is considered a major cause of TJ opening and barrier permeabilization ([@B1]), which is consistent with the results in [Figure 2C](#F2){ref-type="fig"}.

![Effects of NF-κB activation in *Prkci*^flox/flox^ Vil-CRE± (KO) villus enterocytes. Frozen sections of villi from control (lm), KO, or KO mice treated with sulfasalazine SS were processed with anti--phospho Ser-21 nonmuscle myosin II light chain (pMLC, red channel) antibody. Note that changes in signal were observed in epithelia and not in lamina propria cells. Bar, 10 μm.](2186fig8){#F8}

Finally, to assess directly NF-κB transcriptional activity, we measured CXCL-1 (GRO-1) and CXCL-2 (GRO-2) mRNAs, broadly accepted as NF-κB target genes ([@B18]; [@B56]). Reverse transcription-PCR (RT-PCR) was performed on RNA extracts from purified enterocytes. Both cytokines were found to be significantly increased (ninefold and fivefold, respectively) in KO enterocytes. However, KO animals treated with SS or Y27628 did not show increased CXCL-1 mRNA levels ([Figure 9](#F9){ref-type="fig"}). These data provide additional evidence for NF-κB activation in the absence of PKCι, likely through the canonical IKK pathway via ROCK.

![Cytokine mRNA expression from isolated small intestine enterocytes from *Prkci*^flox/flox^ Vil-CRE± (KO). Each data set comprises mRNAs from two different groups of animals for control littermates (lm) and KO, except for CXCL-1, which also comprises animals treated with oral SS or intraperitoneal Y27628. For each group, values were normalized to one control animal (lm). Horizontal lines represent average. Vimentin and IL-1β mRNA were measured in preparations of isolated enterocytes (E) or spleen (S) from the same animals to assess connective tissue contamination of the epithelium preparations. Kruskal--Wallis test, H~0~ = control lm and KO populations are equal, *p* \< 0.005 (CXCL-1), *p* \< 0.05 (CXCL-2), *p* \< 0.05 (IL-1α), SS or Y27628 groups, not significant. For vimentin and IL-1b, H~0~ = spleen data are equal to enterocytes, *p* \< 0.001.](2186fig9){#F9}

Two other cytokines have been found to be essential in the development of intestinal inflammation: interleukin 1α (IL-1α) and IL-10. The former is proinflammatory, and the latter is anti-inflammatory ([@B38]; [@B63]). These cytokines have been commonly studied in myeloid cells but are known to be secreted by the intestinal epithelium as well ([@B6]; [@B53]; [@B63]). IL-1α mRNA was significantly increased in the KO. Conversely, IL-10 in the KO was found to be ∼25% the levels of the control animals, a significant reduction ([Figure 9](#F9){ref-type="fig"}). It is worth highlighting that these two cytokines are not known to be directly under NF-κB transcriptional control. The possibility that these results may be due to a contamination with cells of mesenchymal lineage, including myeloid cells, was controlled by measuring mRNAs that are not expressed in epithelial cells. Spleen parenchymal cells (S) were used as a positive control of mesenchymal/myeloid lineage cells and were compared with purified enterocytes (E) from the same animal ([Figure 9](#F9){ref-type="fig"}). Two mRNAs not expressed in epithelial cells were used. Vimentin mRNA showed a 200-fold enrichment of epithelial over mesenchymal RNAs in our preparations. IL-1β mRNA is transcribed at lower levels than cytoskeletal proteins mRNAs. By in situ hybridization, it has been shown that IL-1β mRNA is expressed in lamina propria but not in epithelial cells in the intestine ([@B74]). Because IL-1β expression was 400-fold higher in a spleen cells compared with enterocytes, we further concluded that the contamination of our purified enterocyte mRNA with RNAs from other cells was minimal. These data support the conclusion that basal (unstimulated) cytokine expression in *Prkc*i^flox/flox^ Vil-CRE+ enterocytes is proinflammatory via NF-κB and possibly other, unidentified pathways as well.

DISCUSSION
==========

This work focused on innate immunity activity in epithelial cells under minimal exogenous proinflammatory signaling: The goal was to identify epithelium-specific functions of polarity complex aPKC. The evidence leads to two conclusions. First, aPKC is dispensable for the maintenance of apicobasal polarity in the short term, that is, the 2-d lifespan of postmitotic villus enterocytes. Second, aPKC is indeed a negative regulator of NF-κB activity in enterocytes. The latter is a tissue-specific effect of aPKC and indicates that results from other cell types, in which aPKC *activates* NF-κB, cannot be generalized to epithelia. Furthermore, although there are commonalities between epithelia in the small and large intestine, the conclusions from this work should not be generalized to colon epithelium.

Apical polarity persists in PKCι KO enterocytes after PKCζ is spontaneously down-regulated at the crypt/villus boundary for the short lifespan of the villus enterocytes. The *Prkci*^flox/flox^ Vil-CRE animals showed normal weight gains, in stark contrast with the phenotype of mutations disturbing apical membrane traffic, such as Rab8 ([@B62]) and Myo5b ([@B12]) KO models. Even defects in single apical transporters, such as the GLUT8 transporter, have been shown to affect body weight ([@B15]). Overall, therefore, nutrient absorption in PKCι KO animals must be normal. On the other hand, changes in the distribution of direct aPKC targets such as LLGL2 and ROCK were observed, confirming the loss of aPKC activity.

The loss of ezrin phosphorylation in the PKCι KO supports our previous observation in Caco-2 cells that PKCι phosphorylates ezrin ([@B72]). The rapid turnover of the ezrin activation phosphosite (T567; [@B69]) is consistent with dephosphorylation immediately after PKCζ is down-regulated in the PKCι KO enterocytes. This issue has been controversial: Mst4 was also shown to phosphorylate ezrin in intestinal epithelia ([@B67]). Both splice variants of LKB1 are activated by aPKC ([@B75]). Therefore the results shown here demonstrate that PKCι is key for ezrin phosphorylation, either directly or indirectly via the LKB1-Mst4 pathway, and are consistent with observations in other systems ([@B42]).

It may be counterintuitive that KO enterocytes still show a normal brush border ([Figure 4C](#F4){ref-type="fig"}). In ezrin-knockout mice, enterocytes lacking ezrin throughout their differentiation still show microvilli, albeit ones that are shorter and more disorganized ([@B61]). PKCι KO enterocytes, on the other hand, show a 15-fold decrease in apical ezrin but still display a sizable apical accumulation of ezrin. Considering that the ezrin decrease is short-lived due to the limited lifespan of the cells, it is not surprising that the brush border structure is not affected. In summary, the data suggest that persistence of a polarized phenotype may be more related to the temporal stability of the structure. In other words, the PKCι-defective enterocytes would display a phenotype only if the dephosphorylation of aPKC targets and its effects appear within a 2-d period. Conversely, Par3 localizes in an aPKC-independent manner through the NTD and PDZ domains ([@B13]). In fact, Par3 localization to the adherens junctions drives aPKC-Par6 localization to the TJ ([@B30]). Therefore, predictably, Par3 remained polarized in the absence of aPKC activity.

Despite the normal appearance of ZO-1 and occludin, the decreased expression of claudin-4 may partially explain the increased solute permeability in PKCι-deficient enterocytes: in lung cells, claudin-4 knockout increases solute permeability with no changes in ion permeability ([@B34]). In addition, claudin-4 is down-regulated in ulcerative colitis ([@B54]). On the other hand, innate immunity mechanisms increase TJ permeability by multiple mechanisms, including NF-κB--dependent assembly of myosin II via MLCK activation ([@B55]) and interferon γ--dependent pathways ([@B8]). In addition, PKCι has been shown to modulate claudin-2 as well ([@B44]). Finally, there is extensive evidence that ROCK activation mediates opening of TJs ([@B33]; [@B14]) by inhibiting MLC dephosphorylation ([@B35]). The results from the PKCι KO mouse presented here strongly suggest that, in addition to "local" regulation of nonmuscle myosin II via ROCK at the junctional level, aPKC exerts control over the canonical NF-κB activation pathway and, accordingly, is involved in transcriptional control. All of these non--mutually exclusive mechanisms can explain the increase in TJ permeability.

Of importance, although a threefold increase in solute permeability seems modest, it mimics the levels of increased permeability in IBD patients in remission or in asymptomatic relatives ([@B9]), including the barrier permeability in the small intestine ([@B10]). Accordingly, we speculate that the conditional PKCι-null mouse model might be clinically relevant to mimic increased barrier permeability close to the threshold that triggers colitis.

aPKC defect increases NF-κB activation
--------------------------------------

The evidence presented here strongly supports activation of NF-κB in epithelial cells within an environment with low levels of inflammatory stimuli as compared with the colon. Bearing in mind that in other cell types, aPKC activates NF-κB ([@B16]), the identity of the pathway(s) connecting a highly localized aPKC to inhibition of NF-κB activation is important. Two pieces of evidence suggest that the effect must be exerted on the canonical NF-κB activation pathway. First, expression of constitutively active PKCι results in IkB accumulation ([@B21]). Second, PKCι deficiency increased pSer 536 relA signal ([Figure 7, C and D](#F7){ref-type="fig"}), an effect rescued by two different small molecules (SS and Y27632), which both inhibit IKKs directly or indirectly via ROCK. On the other hand, the transcriptional effects of an aPKC defect on IL-1α and IL-10 suggest that additional pathways might be involved. Evidence supports the possibility that aPKC might signal through STAT3 ([@B26]), which in turn activates IL-10. Moreover, aPKC also signals through CREB-binding protein (CBP) by direct phosphorylation in S436 ([@B29]). In turn, CBP is involved in the control of NF-κB and IL-10 transcription ([@B2]; [@B51]). Dissecting all of these possible mechanisms is beyond the scope of this work.

Evidence from other laboratories has been contradictory regarding the effects of the Rho pathway in NF-κB activation. However, there is support for the notion that RhoA potentiates NF-κB activation ([@B57]; [@B7]). On the basis of the poor effect of Y27632 on phospho-relA in lamina propria cells, we speculate that this pathway of aPKC inhibition of ROCK, which in turn activates IKK ([@B4]; [@B36]), might provide clues for the tissue specificity of the effect of PKCι on NF-κB. Additional studies are necessary to further test this hypothesis.

Recently [@B26] confirmed our original observation that Par3 is also an inhibitor of NF-κB ([@B21]) in carcinoma cells. The data presented here, however, challenge the notion that loss of Par3 activates NF-κB through the activation of aPKC. The results in this work, conversely, support our interpretation that the anti--NF-κB activity of Par3 is exerted independently of aPKC ([@B21]). It is possible that the differences arise from the use of different cell types in culture in the cited work and the analysis in vivo in this work.

In summary, PKCι expression in differentiated enterocytes is critical to control transcription factors that mediate effects on MLC and barrier permeability (NF-κB), proinflammatory cytokine transcription inhibition (CXCL-1 and -2, IL-1α), and anti-inflammatory cytokine expression (IL-10, possibly through STAT3 or CBP). All of these mechanisms seem to be additional to apicobasal polarity functions and sufficient to predispose the intestinal mucosa to inflammation. It seems reasonable to speculate that this function might be general to polarized epithelia under conditions of low inflammatory stimulation. Whether this mechanism interacts with, for example, activated TLR4 or TNFR pathways remains to be determined. However, the down-regulation of aPKC during intestinal inflammation is likely to contribute to the intensity or persistence of the inflammatory response. The data presented here add to a growing body of evidence ([@B6]; [@B53]; [@B63]) that intestinal epithelial cells are important regulators of inflammation, not only as a passive barrier, but also through the secretion of cytokines.

MATERIALS AND METHODS
=====================

Animal model
------------

All studies in animals were conducted according to guidelines in the Public Health Service Guide for the Care and Use of Laboratory Animals. The animal protocol was approved by the local Institutional Animal Care and Use Committee. Embryonic stem cells carrying the recombinant insertions in the *Prkci* gene shown in [Figure 1A](#F1){ref-type="fig"} were obtained from the International Mouse Knockout Consortium ([www.mousephenotype.org/](http://www.mousephenotype.org); Project 71671). The cells were selected, cloned, and injected into mouse blastocysts in the C57BL/6 genomic background. For genotyping, we used the following primers ([Figure 1A](#F1){ref-type="fig"}, GenBank accession JN952602.1):14729: CAGGCCCTCTGCAGAGATAGTTC21131: GGCTGCATACGCTTGATCCG22182: CCAACAAAAGTCCCTCTCCCCT

Genotyping PCR was performed as follows: primers 2 and 3 were used for germline transmission, amplimer 1051 base pairs; primers 1--3 yielded a 350--base pair amplimer in WT and a 550--base pair amplimer in the flox insertion. After germline transmission was verified, the animals were bred with B6(C3)-Tg(Pgk1-FLPo)10Sykr/J mice (Jackson Laboratory) to remove the FRT insert. After removal of the Neo cassette, animals carrying the flox insertions flanking exon 4 were backcrossed with WT C57BL/6 mice for five generations. Finally, these animals were further bred with B6.Cg-Tg(Vil-cre)997Gum/J (Jackson Laboratory). *Prkci*^flox*/*−^ Vil-CRE+ or *Prkci*^flox/flox^ littermates were used as controls. These animals were cohoused with the *Prkci*^flox/flox^ Vil-CRE+ animals. Expression of PKCι was verified independently by immunofluorescence in each animal.

Reagents
--------

Reagents used were as follows: Texas red--dextran (3000 Da; Invitrogen, Carlsbad, CA), Alexa Fluor 546--phalloidin (Invitrogen), SS (Fluka, Sigma-Aldrich, St. Louis, MO), and Y27632 (Tocris, R&D Systems, Minneapolis, MN). The antibodies used in this work were PKCζ (directed against a synthetic peptide comprising amino acids 174--203 of the human orthologue; human--mouse similarity in this region, 100%; identity, 90%; ThermoFisher, Waltham, MA), PKCι (5282; Abcam, Cambridge, MA), pT555 PKCζ (GeneTex, Irvine, CA), CD68 (Bio-Rad, Hercules, CA), ezrin (Abcam), pT567 ezrin (Cell Signaling, Danvers, MA), intestinal alkaline phosphatase (iAP; Accurate), ZO-1 (Invitrogen), Par3 (Millipore, Billerica, MA), NF-κB p65 relA (Cell Signaling), occludin (ThermoFisher), NHE3 (Abcam), claudin-4 (Invitrogen), LLGL2 (Bioss, Woburn, MA), Na+-K+ ATPase (Accurate, Westbury, NY), pSer21-MLC (Abcam), pSer 536 relA (Invitrogen), and ROCK1/2 (Assay Biotech, Sunnyvale, CA).

Intestinal permeability
-----------------------

The animals were food starved overnight but allowed free access to water. Then they received 100 μl of 4 mg/ml 3-kDa Texas red--dextran via stomach gavage. After 3 h, the animals were killed by deep anesthesia and exsanguination. In all cases, a Texas red--dextran bolus was macroscopically localized to the small intestine after death. Samples of the blood were anticoagulated with 2 mM EDTA, and plasma was separated by centrifugation. Texas red fluorescence was measured with a SpectraMax Gemini EM fluorometer (Molecular Devices) after dilution. Background in plasma from animals not receiving fluorescent dextran was subtracted. The results from different groups of animals are expressed as fluorescence relative to one control animal in the same group.

Frozen sections, immunofluorescence, and electron microscopy
------------------------------------------------------------

Methods for these techniques have been published ([@B3]; [@B47]). Immunofluorescence using phosphoepitope antibodies was performed after fixation in trichloroacetic acid ([@B27]). All immunofluorescence images were collected with a Leica SP5 confocal microscope, and semiquantitative image analysis was performed with Leica software as described later. Electron microscope samples were prepared by standard techniques, and images were obtained with a Jeol JEM-1400 instrument, using Gatan software.

For fluorescence image analysis, pixel quantification was performed as described previously ([@B71]). Briefly, images were collected, avoiding pixel saturation in the channel to be measured. ROIs matching the size of positive signal images were defined and used throughout the sampling. Examples of ROIs are shown in [Figures 5A](#F5){ref-type="fig"}, [6A](#F5){ref-type="fig"}, and [7C](#F5){ref-type="fig"} (yellow squares). The analyses were conducted blindly, and ROIs were positioned on the desired region of cells (e.g., apical edge, cytoplasm, or nucleus) in the 4′,6-diamidino-2-phenylindole (DAPI) channel to randomize the sampling. One average of pixel values in the ROI per cell was collected and used for statistics, which comprised several cells from different animals.

RT-quantitative PCR
-------------------

Immediately after euthanasia, small intestine epithelial cells were purified by extraction in EDTA-dithiothreitol as described ([@B49]), with five to eight cycles of centrifugation and resuspension to wash mucus and separate nonepithelial cells. Spleen parenchymal cells were obtained by cutting the capsule with a razor blade in phosphate-buffered saline and shaking the organ with tweezers to separate the capsule. The resulting cell suspension was pipetted several times to separate debris. RNA was purified using mechanical homogenization by passing samples through needles 18G1^1/2^ and 20G1^1/2^ several times and TRIzol Reagent (Ambion Thermo Fisher Scientific). cDNA was synthesized from 1 μg of RNA using the iScript cDNA synthesis kit (Bio-Rad). Quantitative PCR amplification was performed using TaqMan gene expression assays (Life Technologies), including gene-specific primer and probe sets specifically designed against our molecules of interest (Mm04207460_m1 for CXCL-1, Mm00436450_m1 for CXCL-2, Mm00434151_m1 for IL-10, Mm00439620_m1 for IL-1α, Mm01333430-m1 for vimentin, and Mm00439620-m1 for IL-1β). The relative quantification method (ΔΔ*Ct*) was used for analysis of mRNA fold change using endogenous control glyceraldehyde-3-phosphate dehydrogenase for normalization.

Sulfasalazine and Y27632 treatments
-----------------------------------

Sulfasalazine was dissolved at 37°C in tap water supplemented with 50 mM sucrose (for taste). The pH was titered to 7.0 with NaOH. Accordingly, the SS vehicle for controls was tap water supplemented with 5 mM NaCl and 50 mM sucrose. The animals were allowed to drink ad libitum.

The Y27632 treatment was slightly modified from published protocols. The dose was at the low range of standard doses (2 mg/kg; [@B41]) and repeated twice a day. The rationale for this dosing was based on published bioavailability studies showing Y27632 half-life of ∼90 min after intraperitoneal administration ([@B40]). We aimed at peak plasma concentrations of ∼1 μM. In addition, Y27632 doses were calculated to be above the *EC*~50~ of 0.14 μM for ROCK ([@B60]) for much of the day, thus justifying two injections per day. At concentrations \>20 μM, Y27632 blocks other kinases ([@B60]), so higher doses were avoided. In summary, Y27628 was injected intraperitoneally, at 2 mg/kg twice a day.

Statistics
----------

For normal distribution values, statistical significance was determined by Student's *t* test. For data not conforming to normal distribution, the nonparametric Kruskal--Wallis test was used.

This article was published online ahead of print in MBoC in Press (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E16-02-0086>) on May 25, 2016.
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aPKC

:   atypical protein kinase C

CBP

:   CREB-binding protein

IBD

:   inflammatory bowel disease

IL

:   interleukin

LLGL2

:   homologue of *Drosophila* lethal giant larvae

MLC

:   myosin II regulatory light chain

NF-kB

:   nuclear factor kappa beta

NHE3

:   sodium-proton exchanger 3

Par

:   homologues of partition-deficient mutations in *C. elegans*

*Prkci*

:   murine gene encoding PKC lambda

ROCK

:   Rho-associated protein kinase

SS

:   sulfasalazine

TJ

:   tight junction

TLR4

:   Toll-like receptor 4

TNFR

:   tumor necrosis factor receptor

Vil

:   villin.
